MediWound (NASDAQ:MDWD) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of MediWound (NASDAQ:MDWD) in a research note released on Friday, Benzinga reports. HC Wainwright currently has a $28.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on the stock. StockNews.com upgraded shares of MediWound to a sell rating in a research report on Monday, August 5th. Maxim Group boosted their target price on shares of MediWound from $25.00 to $30.00 and gave the company a buy rating in a research report on Tuesday, July 16th.

MediWound Stock Performance

Shares of MediWound stock opened at $16.81 on Friday. The stock has a market capitalization of $156.06 million, a PE ratio of -12.18 and a beta of 0.83. MediWound has a 52-week low of $7.45 and a 52-week high of $24.00. The company has a 50-day simple moving average of $17.62 and a two-hundred day simple moving average of $17.23.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.26). The company had revenue of $5.06 million for the quarter, compared to analysts’ expectations of $5.07 million. MediWound had a negative net margin of 99.17% and a negative return on equity of 52.49%. As a group, equities research analysts forecast that MediWound will post -2.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Rhumbline Advisers purchased a new stake in MediWound in the 2nd quarter worth $131,000. Bank of New York Mellon Corp purchased a new position in shares of MediWound in the second quarter valued at about $342,000. Janney Montgomery Scott LLC bought a new position in shares of MediWound in the first quarter worth about $427,000. Silverberg Bernstein Capital Management LLC grew its position in shares of MediWound by 7.8% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock worth $1,214,000 after purchasing an additional 6,200 shares in the last quarter. Finally, Essex Investment Management Co. LLC raised its stake in MediWound by 241.6% during the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after purchasing an additional 93,705 shares during the period. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.